Effect of breast cancer adjuvant therapies on potential biomarkers of pulmonary inflammation

The aim of this study was to investigate the effect of breast cancer adjuvant therapies on the levels of circulating surfactant protein-D (SP-D), C-Reactive protein (CRP) and soluble receptor for advanced glycation end-products (sRAGE), as potential biomarkers of subclinical pulmonary inflammation....

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2012-11, Vol.32 (11), p.4993-5002
Main Authors: Piperis, Maria, Provatopoulou, Xeni, Sagkriotis, Alexandros, Kalogera, Eleni, Ampatzoglou, Emmanouil, Zografos, George C, Athanasiou, Eleni, Gounaris, Antonia
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Monoclonal, Humanized - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers - blood
Breast Neoplasms - therapy
C-Reactive Protein - analysis
Chemoradiotherapy - adverse effects
Chemotherapy, Adjuvant - adverse effects
Enzyme-Linked Immunosorbent Assay
Female
Humans
Middle Aged
Pneumonia - blood
Pneumonia - etiology
Pulmonary Surfactant-Associated Protein D - blood
Radiotherapy, Adjuvant - adverse effects
Receptor for Advanced Glycation End Products
Receptors, Immunologic - blood
Trastuzumab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate the effect of breast cancer adjuvant therapies on the levels of circulating surfactant protein-D (SP-D), C-Reactive protein (CRP) and soluble receptor for advanced glycation end-products (sRAGE), as potential biomarkers of subclinical pulmonary inflammation. The soluble molecules were serially determined in 38 patients, prior to the initiation of radiation therapy (RT) and during adjuvant treatment, using immunoassays. Significantly higher levels of all three biomarkers were observed in patients prior to the initiation of RT compared to healthy controls (CRP: p
ISSN:1791-7530